IL-5

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
Wednesday, November 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.

Revolo Biotherapeutics Presents New Data Demonstrating Long-Lasting Effect of ‘1104 in a Food Allergy Model at the 2023 AAAAI Annual Meeting

Retrieved on: 
Tuesday, February 28, 2023
OVA, Eosinophilic esophagitis, Thermoregulation, Mouse, Half-life, Immune system, PD, B cell, Food allergy, American Academy of Allergy, Asthma, and Immunology, Immunoglobulin E, Biomarker, Patient, Chemokine, IL-5, Immunosuppression, AAAAI, Inflammation, Plasma, Autoimmunity, Serum, Asthma, Hypothermia, Cytokine, Anaphylaxis, American Academy, Ovalbumin, Vaccine

The data demonstrate the long-lasting effect of ‘1104 in a food allergy model, including the reduction of anti-inflammatory markers and improvements in clinical scores, highlighting its potential as an allergen-agnostic therapeutic for the treatment of food allergy.

Key Points: 
  • The data demonstrate the long-lasting effect of ‘1104 in a food allergy model, including the reduction of anti-inflammatory markers and improvements in clinical scores, highlighting its potential as an allergen-agnostic therapeutic for the treatment of food allergy.
  • “We are very pleased to continue to demonstrate the positive effect of ‘1104 in multiple allergic disease settings, including now in food allergy,” said Jonathan Rigby, Chief Executive Officer of Revolo Bio.
  • Some mice dosed with 80ug/kg and 800ug/kg of ‘1104 were then re-challenged and evaluated for these markers at 38 days after sensitization (i.e.
  • These data indicate a long-term suppression of indices of anaphylaxis in this model.

XOLAIR Drug Insights and Market Forecasts, 2019-2021 & 2022-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Pharmaceutical, Health, Clinical Trials, Clinical trial, Basophil, Syringe, IL-5, Omalizumab, Blood, Immunoglobulin G, Research, SWOT, Polyp (medicine), Inflammation, Downregulation and upregulation, SC, Eosinophil, B cell, Immunoglobulin E, FDA, Phase, United Kingdom, Asthma, CIU, Cell, Pharmaceutical industry, Vaccine, Petroleum jelly, Risk management, FCER1

"XOLAIR Drug Insight and Market Forecast - 2032" report provides comprehensive insights about XOLAIR for Nasal Polyposis in the 7MM.

Key Points: 
  • "XOLAIR Drug Insight and Market Forecast - 2032" report provides comprehensive insights about XOLAIR for Nasal Polyposis in the 7MM.
  • The report also highlights the XOLAIR research and development activity in Nasal Polyposis details across the United States, Europe and Japan.
  • What are the forecasted sales of XOLAIR in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available in Nasal Polyposis and how are they giving competition to XOLAIR for Nasal Polyposis?

Chinese Medical Journal Review Offers Valuable Insights into Severe Asthma

Retrieved on: 
Wednesday, December 14, 2022
Respiratory Medicine, Cytokine, Azithromycin, Bronchial thermoplasty, Risk, Imperial College London, Diagnosis, ICS, Chinese, Bronchial hyperresponsiveness, Biomarker, Asthma, IL-5, Chinese Medical Journal, Antibody, Immunoglobulin E, Interleukin, Epigenetics of diabetes Type 2, Phenotype, Pharmaceutical industry

This paper was made available online on May 28, 2022, and was published in Volume 135, Issue 10, of the Chinese Medical Journal .

Key Points: 
  • This paper was made available online on May 28, 2022, and was published in Volume 135, Issue 10, of the Chinese Medical Journal .
  • However, oral corticosteroid therapy for severe asthma could be minimized by introducing antibody therapies, which are targeted for those with Type 2 inflammation.
  • Prof. Chung concludes, "Antibody treatments targeted at the Type-2 targets, such as anti-IL5, anti-IL5Ra, and anti-IL4Ra antibodies, are now available for treating severe eosinophilic asthma, in addition to anti-immunoglobulin E antibody for severe allergic asthma.
  • In summary, molecular phenotyping of the airway inflammatory process is already paving the way towards the precision treatment of severe asthma and will go on expanding.

Biosimilar Interleukins Global Market Report 2022: Rising Prevalence of Autoimmune Conditions Spurring Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022
Health, Pharmaceutical, Acquisition, Distribution, Pharmacy, Johns Hopkins University, Degenerative disease, Growth, Application, Population, IBD, IL-5, Cancer, Sanofi, Asthma, Rheumatoid arthritis, IL-6, Interleukin 17, Interleukin, Psoriasis, Cystine, Prevalence, Cell, Autoimmune disease, Inflammatory bowel disease, Generic drug, Vaccine

The "Biosimilar Interleukins Global Market Report 2022: By Type, By Application, By Distribution" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Interleukins Global Market Report 2022: By Type, By Application, By Distribution" report has been added to ResearchAndMarkets.com's offering.
  • The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period.
  • Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.
  • Synthorx, Inc. is a US-based biotechnology company focused on developing interleukins for people suffering from cancer and autoimmune disorders.

Biosimilar Interleukins Global (IL-17, IL-23, IL-1, IL-5, IL-6, Others) Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 21, 2021
Biotechnology, Hospitals, Health, Pharmaceutical, Clinical Trials, Autoimmune disease, IL-5, Growth, Interleukin, Degenerative disease, Cell, British Society for Immunology, Society, Psoriasis, IL-6, Rheumatoid arthritis, Immunology, COVID-19, Asthma, IBD, Inflammatory bowel disease, Incidence, Sorrento, Cancer, Prevalence, Pharmacy, Generic drug, Vaccine

The "Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical.
  • The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases.
  • The biosimilar interleukins market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, and others.

Interleukin Inhibitors Global Market Report 2021: Focus on IL-17, IL-23, IL-1, IL-5, IL-6, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 8, 2021
Health, Pharmaceutical, Johnson & Johnson, IL-6, Term of patent, Homeostasis, Inflammation, Biotechnology, Immunotherapy, Novartis, GlaxoSmithKline, Ustekinumab, Degenerative disease, Inflammatory bowel disease, Patient, Sanofi, IL, Psoriasis, Asthma, Lists of countries and territories, Secukinumab, Autoimmunity, Gedeon Richter, Rheumatoid arthritis, Canakinumab, COVID-19, Pharmacy, Interleukin, IL-5, Growth, AstraZeneca, Arthritis, Eli Lilly, Regeneron Pharmaceuticals, Roche, Teva Pharmaceuticals, Pharmaceutical industry

The "Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals.
  • The interleukin inhibitors market consists of the sales of interleukin inhibitors such as interleukin -1, interleukin -5, interleukin -6, interleukin -17, interleukin 23, by companies that manufacture them.
  • An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitors market.

Interleukin Inhibitors Global Markets Report 2020-2030: Focus on IL-17, IL-23, IL-1, IL-5, IL-6 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 19, 2021
Health, Pharmaceutical, Secukinumab, Sanofi, Regeneron Pharmaceuticals, Gedeon Richter, Immunotherapy, Ustekinumab, Inflammation, Rheumatoid arthritis, Johnson & Johnson, Pharmacy, Teva Pharmaceuticals, Asthma, IL-5, Canakinumab, IL-6, Autoimmunity, Homeostasis, Psoriasis, Biotechnology, Degenerative disease, Lists of countries and territories, Patient, GlaxoSmithKline, Arthritis, Novartis, IL, Psoriatic arthritis, Roche, COVID-19, Eli Lilly, Interleukin, AstraZeneca, Inflammatory bowel disease, Pharmaceutical industry

The "Interleukin Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interleukin Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.
  • The interleukin inhibitors market consists of the sales of interleukin inhibitors such as interleukin -1, interleukin -5, interleukin -6, interleukin -17, interleukin 23, by companies that manufacture them.
  • Major companies in the interleukins sector are focusing on developing biosimilars for interleukin inhibitors.